Clopidogrel 75mg tablets
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Clopidogrel 75mg Tablets: Bioequivalence and Pharmacokinetics
Bioequivalence of Clopidogrel 75mg Tablets
Bioequivalence Studies in Healthy Volunteers
Several studies have assessed the bioequivalence of different formulations of clopidogrel 75mg tablets. A study involving 64 healthy subjects under fasting conditions demonstrated that two formulations of clopidogrel were bioequivalent in terms of both the rate and extent of absorption, as indicated by the 90% confidence intervals for AUClast and Cmax falling within the predefined range of 80.00% to 125.00%. Similarly, another study conducted in healthy Argentinian volunteers confirmed the bioequivalence of a generic formulation of clopidogrel to the branded formulation, with no significant differences in pharmacokinetic parameters between the groups.
Comparative Bioavailability
A study comparing the bioavailability of two clopidogrel formulations in 42 volunteers found that the geometric mean ratios for AUC0-t, AUC0-inf, and Cmax were within the acceptable bioequivalence range of 80% to 125%. Another study with 24 healthy subjects under fasting conditions also concluded that the test and reference formulations were bioequivalent based on similar pharmacokinetic parameters.
Pharmacokinetics and Dosing
Pharmacokinetics Under Fed and Fasted Conditions
The pharmacokinetics of clopidogrel 75mg tablets have been evaluated under both fed and fasted conditions. In a study involving 66 healthy Chinese volunteers, the geometric least-squares mean ratios for Cmax and AUC0-t were within the bioequivalence range for both conditions, indicating that food intake does not significantly affect the bioavailability of clopidogrel.
Loading Dose and Maintenance Dose
The effectiveness of different dosing regimens of clopidogrel has also been studied. A study comparing a 75mg daily maintenance dose with a 150mg dose in patients with ST-segment elevation acute myocardial infarction (STEMI) found that the higher dose resulted in significantly greater inhibition of platelet aggregation and a reduction in inflammation. Another study confirmed that a 150mg maintenance dose provided more intense inhibition of platelet aggregation compared to the standard 75mg dose.
Clinical Implications
Antiplatelet and Anti-inflammatory Effects
Clopidogrel is widely used for its antiplatelet effects, particularly in reducing the risk of thrombotic events in patients undergoing procedures like percutaneous coronary intervention (PCI). Studies have shown that a higher maintenance dose of clopidogrel (150mg) is more effective in patients with poor responsiveness to the standard 75mg dose, leading to better clinical outcomes .
Variability in Response
The response to clopidogrel can vary significantly among individuals. Factors such as baseline platelet reactivity and patient weight can influence the drug's effectiveness. For instance, patients with higher baseline platelet reactivity tend to show a greater response to clopidogrel, while those with higher body weight may require higher doses to achieve the desired antiplatelet effect.
Conclusion
Clopidogrel 75mg tablets have been extensively studied for their bioequivalence and pharmacokinetics. Multiple studies confirm that different formulations of clopidogrel are bioequivalent, ensuring consistent therapeutic effects. Additionally, higher maintenance doses may be beneficial for certain patient populations, particularly those with poor responsiveness to the standard dose. Understanding these factors can help optimize clopidogrel therapy for better clinical outcomes.
Sources and full results
Most relevant research papers on this topic